by Instem Team | Mar 18, 2026 | Clinical
Open-source technology has reshaped nearly every data-driven industry, including the life sciences. Among open-source tools, R has emerged as a strong choice for modern biostatistics, clinical analytics, and research. The flexibility, vast package availability, and...
by Instem Team | Mar 18, 2026 | In Silico & Data Insights, Regulatory Submission, Study Management
Lead Optimization Once a selection of hits has been identified, the process of drug discovery moves to refine initial hits with promising biological activity into validated leads that are optimized for potency, selectivity, and drug-like properties. Lead optimization...
by Instem Team | Mar 15, 2026 | Resources
Vivarium managers and research staff face increasing pressure to maintain well‑organized, compliant, and high‑integrity colony data while supporting fast‑paced research timelines. Legacy spreadsheets and disconnected tools make it difficult to track breeding programs,...
by Instem Team | Mar 12, 2026 | Clinical
Across the life sciences sector, pressure on R&D productivity and profitability is intensifying. Pricing constraints, patent expirations, and organizational restructuring are forcing pharmaceutical and biotech companies to do more with fewer resources. At the same...
by Instem Team | Mar 11, 2026 | In Silico & Data Insights, Regulatory Submission, Study Management
Discovery Given that a single high-throughput screening campaign may evaluate over 2 million compounds, discovery teams must move through terabytes of data before deciding to prioritize only a handful of compounds after target identification. When data and rationale...
